{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:14:17Z","timestamp":1791476057276,"version":"4.3.4"},"reference-count":115,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG\\u2013FOR 2886 PANDORA\\u2013B01"],"award-info":[{"award-number":["DFG\\u2013FOR 2886 PANDORA\\u2013B01"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["493624887"],"award-info":[{"award-number":["493624887"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["101001866-INSPIRE"],"award-info":[{"award-number":["101001866-INSPIRE"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["101007757"],"award-info":[{"award-number":["101007757"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.autrev.2025.103839","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T19:47:39Z","timestamp":1748720859000},"page":"103839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Advances in precision medicine in imaging and therapeutic strategies for psoriatic disease"],"prefix":"10.1016","volume":"24","author":[{"given":"Thorben","family":"Witte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Minopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman Michael","family":"Drzeniek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Torgutalp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sabat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Casteleyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Albach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Fagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alen","family":"Zabotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"K\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnd","family":"Kleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.autrev.2025.103839_bb0005","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1365-2230.2001.00832.x","article-title":"Psoriasis--epidemiology and clinical spectrum","volume":"26","author":"Christophers","year":"2001","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103839_bb0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.autrev.2025.103839_bb0015","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/kex323","article-title":"Interval between onset of psoriasis and psoriatic arthritis comparing the UK clinical practice research datalink with a hospital-based cohort","volume":"56","author":"Tillett","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2025.103839_bb0020","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/art.24172","article-title":"Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study","volume":"61","author":"Wilson","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103839_bb0025","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64 Suppl 2(Suppl 2)","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2025.103839_bb0030","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1136\/annrheumdis-2012-201299","article-title":"Obesity and the risk of psoriatic arthritis: a population-based study","volume":"71","author":"Love","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2025.103839_bb0035","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.39494","article-title":"The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study","volume":"68","author":"Eder","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2025.103839_bb0040","first-page":"1856","article-title":"Risk factors for psoriatic arthritis development in psoriasis patients: myths, pitfalls, and pearls","volume":"42","author":"Patt","year":"2024","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103839_bb0045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11926-020-00891-x","article-title":"From psoriasis to psoriatic arthritis: insights from imaging on the transition to psoriatic arthritis and implications for arthritis prevention","volume":"22","author":"Zabotti","year":"2020","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"10.1016\/j.autrev.2025.103839_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004314","article-title":"Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage","volume":"10","author":"Zabotti","year":"2024","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.autrev.2025.103839_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003143","article-title":"Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce","volume":"9","author":"De Marco","year":"2023","journal-title":"RMD Open"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2025.103839_bb0060","doi-asserted-by":"crossref","first-page":"i71","DOI":"10.1136\/ard.2010.144097","article-title":"The early phase of psoriatic arthritis","volume":"70","author":"McGonagle","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2025.103839_bb0065","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/annrheumdis-2012-202608","article-title":"Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis","volume":"72","author":"Tillett","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2025.103839_bb0070","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.41239","article-title":"Association of Structural Entheseal Lesions with an increased risk of progression from psoriasis to psoriatic arthritis","volume":"74","author":"Simon","year":"2022","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2025.103839_bb0075","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103839_bb0080","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s40744-021-00378-w","article-title":"Predictors, risk factors, and incidence rates of psoriatic arthritis development in psoriasis patients: a systematic literature review and Meta-analysis","volume":"8","author":"Zabotti","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"6","key":"10.1016\/j.autrev.2025.103839_bb0085","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","article-title":"Psoriatic arthritis from a mechanistic perspective","volume":"18","author":"Schett","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"9134","key":"10.1016\/j.autrev.2025.103839_bb0090","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(97)12004-9","article-title":"Classification of inflammatory arthritis by enthesitis","volume":"352","author":"McGonagle","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.autrev.2025.103839_bb0095","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/annrheumdis-2016-209334","article-title":"Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis","volume":"76","author":"Thorarensen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 4","key":"10.1016\/j.autrev.2025.103839_bb0100","article-title":"Interleukin-23 in perspective","volume":"60","author":"Sherlock","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2025.103839_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004314","article-title":"Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage","volume":"10","author":"Zabotti","year":"2024","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.autrev.2025.103839_bb0110","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1136\/annrheumdis-2015-208821","article-title":"Subclinical joint inflammation in patients with psoriasis without concomitant psoriatic arthritis: a cross-sectional and longitudinal analysis","volume":"75","author":"Faustini","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2025.103839_bb0115","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/annrheumdis-2017-212681","article-title":"\u2018Deep Koebner\u2019 phenomenon of the flexor tendon-associated accessory pulleys as a novel factor in tenosynovitis and dactylitis in psoriatic arthritis","volume":"77","author":"Tinazzi","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2025.103839_bb0120","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/annrheumdis-2014-206347","article-title":"Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis","volume":"75","author":"Simon","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2025.103839_bb0125","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13075-021-02530-x","article-title":"Biomechanical stress in the context of competitive sports training triggers enthesitis","volume":"23","author":"Simon","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.autrev.2025.103839_bb0130","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/ard.2007.073932","article-title":"Environmental risk factors for the development of psoriatic arthritis: results from a case-control study","volume":"67","author":"Pattison","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103839_bb0135","article-title":"Cardiovascular risk, and therapeutic Management in Obesity and Psoriatic Arthritis","volume":"11","author":"Porta","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103839_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004294","article-title":"Anatomical pattern of entheseal and synovial fibroblast activation in patients with psoriasis and its risk of developing psoriatic arthritis","volume":"10","author":"Corte","year":"2024","journal-title":"RMD Open"},{"issue":"22","key":"10.1016\/j.autrev.2025.103839_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13226880","article-title":"Skin and nail predictors of psoriatic arthritis development: a holistic overview integrating epidemiological and Physiopathological data","volume":"13","author":"Fratton","year":"2024","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.autrev.2025.103839_bb0150","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/art.39973","article-title":"The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort study","volume":"69","author":"Eder","year":"2017","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2025.103839_bb0155","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1093\/rheumatology\/keae060","article-title":"Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis","volume":"63","author":"McGonagle","year":"2024","journal-title":"Rheumatology"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2025.103839_bb0160","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-3083.2009.03363.x","article-title":"Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease","volume":"23","author":"McGonagle","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103839_bb0165","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/myc.13372","article-title":"Characterisation of the nail microbiome in psoriatic and nonpsoriatic patients with onychomycosis","volume":"65","author":"Wang","year":"2022","journal-title":"Mycoses"},{"issue":"5","key":"10.1016\/j.autrev.2025.103839_bb0170","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/exd.14528","article-title":"Dysbiosis of nail microbiome in patients with psoriasis","volume":"31","author":"Wang","year":"2022","journal-title":"Exp Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103839_bb0175","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13075-015-0640-3","article-title":"Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype","volume":"17","author":"FitzGerald","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103839_bb0180","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1038\/ncomms7046","article-title":"Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis","volume":"6","author":"Bowes","year":"2015","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.autrev.2025.103839_bb0185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jdermsci.2022.11.001","article-title":"DNA methylation markers in peripheral blood for psoriatic arthritis","volume":"108","author":"Deng","year":"2022","journal-title":"J Dermatol Sci"},{"issue":"8","key":"10.1016\/j.autrev.2025.103839_bb0190","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41584-020-0454-9","article-title":"Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis","volume":"16","author":"Gracey","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"5931","key":"10.1016\/j.autrev.2025.103839_bb0195","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1126\/science.1171700","article-title":"Topographical and temporal diversity of the human skin microbiome","volume":"324","author":"Grice","year":"2009","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.autrev.2025.103839_bb0200","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chom.2021.05.011","article-title":"Commensal microbiota regulates skin barrier function and repair via signaling through the aryl hydrocarbon receptor","volume":"29","author":"Uberoi","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.autrev.2025.103839_bb0205","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40168-018-0404-9","article-title":"Commensal microbiota modulate gene expression in the skin","volume":"6","author":"Meisel","year":"2018","journal-title":"Microbiome"},{"issue":"6098","key":"10.1016\/j.autrev.2025.103839_bb0210","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1126\/science.1225152","article-title":"Compartmentalized control of skin immunity by resident commensals","volume":"337","author":"Naik","year":"2012","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.autrev.2025.103839_bb0215","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1038\/s41467-019-12253-y","article-title":"Microbe-host interplay in atopic dermatitis and psoriasis","volume":"10","author":"Fyhrquist","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103839_bb0220","article-title":"The role of the gut microbiome in systemic inflammatory disease","volume":"360","author":"Clemente","year":"2018","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.autrev.2025.103839_bb0225","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/art.24389","article-title":"Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis","volume":"60","author":"Ciccia","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103839_bb0230","series-title":"The contribution of the skin microbiome to psoriasis pathogenesis and its implications for therapeutic strategies. Medicina (Kaunas)","volume":"vol. 60(10)","author":"Radaschin","year":"2024"},{"issue":"5","key":"10.1016\/j.autrev.2025.103839_bb0235","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/art.33507","article-title":"Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive \u03b3\/\u03b4 T cells in patients with active ankylosing spondylitis","volume":"64","author":"Kenna","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2025.103839_bb0240","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1136\/annrheumdis-2015-208902","article-title":"IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis","volume":"75","author":"Gracey","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2025.103839_bb0245","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.4049\/jimmunol.1700596","article-title":"Cutting edge: homeostasis of innate lymphoid cells is imbalanced in psoriatic arthritis","volume":"200","author":"Soare","year":"2018","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103839_bb0250","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.rdc.2015.07.006","article-title":"Etiology and pathogenesis of psoriatic arthritis","volume":"41","author":"Barnas","year":"2015","journal-title":"Rheum Dis Clin N Am"},{"issue":"8","key":"10.1016\/j.autrev.2025.103839_bb0255","doi-asserted-by":"crossref","first-page":"356","DOI":"10.4103\/1947-2714.163643","article-title":"The pattern of psoriatic arthritis in Kashmir: a 6-year prospective study","volume":"7","author":"Rather","year":"2015","journal-title":"N Am J Med Sci"},{"issue":"6","key":"10.1016\/j.autrev.2025.103839_bb0260","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s10067-019-04445-0","article-title":"Subclinical synovitis and enthesitis in psoriasis patients and controls by ultrasonography in Saudi Arabia; incidence of psoriatic arthritis during two years","volume":"38","author":"Elnady","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103839_bb0265","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.jid.2021.08.446","article-title":"Differences in clinical features and comorbid burden between HLA-C\u221706:02 carrier groups in >9,000 people with psoriasis","volume":"142","author":"Douroudis","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2025.103839_bb0270","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3899\/jrheum.090218","article-title":"Psoriatic arthritis sine psoriasis","volume":"83","author":"Olivieri","year":"2009","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.autrev.2025.103839_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102400","article-title":"The etiology of rheumatoid arthritis","volume":"110","author":"Scherer","year":"2020","journal-title":"J Autoimmun"},{"issue":"23","key":"10.1016\/j.autrev.2025.103839_bb0280","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103839_bb0285","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X231192315","article-title":"Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis","volume":"15","author":"FitzGerald","year":"2023","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"9","key":"10.1016\/j.autrev.2025.103839_bb0290","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard-2023-224148","article-title":"EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis","volume":"82","author":"Zabotti","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2025.103839_bb0295","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/jbmr.2521","article-title":"Quantitative and qualitative changes of bone in psoriasis and psoriatic arthritis patients","volume":"30","author":"Kocijan","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.autrev.2025.103839_bb0300","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13075-018-1691-z","article-title":"Simultaneous quantification of bone erosions and enthesiophytes in the joints of patients with psoriasis or psoriatic arthritis - effects of age and disease duration","volume":"20","author":"Simon","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.autrev.2025.103839_bb0305","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41584-023-01016-1","article-title":"Imaging in inflammatory arthritis: progress towards precision medicine","volume":"19","author":"Minopoulou","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103839_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.pacs.2020.100220","article-title":"Precision of handheld multispectral optoacoustic tomography for muscle imaging","volume":"21","author":"Wagner","year":"2021","journal-title":"Photoacoustics"},{"issue":"1","key":"10.1016\/j.autrev.2025.103839_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8010063","article-title":"Multispectral optoacoustic tomography: intra- and Interobserver variability using a clinical hybrid approach","volume":"8","author":"Helfen","year":"2019","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.autrev.2025.103839_bb0320","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/rheumatology\/keac346","article-title":"Non-invasive metabolic profiling of inflammation in joints and entheses by multispectral optoacoustic tomography","volume":"62","author":"Tascilar","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103839_bb0325","doi-asserted-by":"crossref","unstructured":"Granger, D.N. and E. Senchenkova, Integrated Systems Physiology\u2014From Cell to Function, in Inflammation and the Microcirculation. 2010, Morgan & Claypool Life Sciences Copyright \u00a9 2010 by Morgan & Claypool Life Sciences.: San Rafael (CA) DOI: https:\/\/doi.org\/10.4199\/c00013ed1v01y201006isp008.","DOI":"10.4199\/C00013ED1V01Y201006ISP008"},{"issue":"2","key":"10.1016\/j.autrev.2025.103839_bb0330","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001497","article-title":"Fluorescence optical imaging: ready for prime time?","volume":"7","author":"Ohrndorf","year":"2021","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.autrev.2025.103839_bb0335","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002682","article-title":"Fluorescence-optical imaging as a promising easy-to-use imaging biomarker to increase early psoriatic arthritis detection in patients with psoriasis: a cross-sectional cohort study with follow-up","volume":"8","author":"Koehm","year":"2022","journal-title":"RMD Open"},{"issue":"suppl 9","key":"10.1016\/j.autrev.2025.103839_bb0340","article-title":"Fibroblast Activation in Psoriasis Patients Assessed by 68Ga-FAPI-04 PET-CT Is Associated with Progression to Psoriatic Arthritis [abstract]","volume":"74","author":"Fagni","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103839_bb0345","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ard.2025.01.051","article-title":"An interpretable machine learning approach for detecting psoriatic arthritis in a UK primary care psoriasis cohort using electronic health records from the clinical practice research datalink","volume":"84","author":"Rudge","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2025.103839_bb0350","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1093\/rheumatology\/keac197","article-title":"Advanced neural networks for classification of MRI in psoriatic arthritis, seronegative, and seropositive rheumatoid arthritis","volume":"61","author":"Folle","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103839_bb0355","article-title":"Deep learning-based classification of inflammatory arthritis by identification of joint shape patterns-how neural networks can tell us where to \u201cdeep dive\u201d clinically","volume":"9","author":"Folle","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.autrev.2025.103839_bb0360","doi-asserted-by":"crossref","first-page":"1574413","DOI":"10.3389\/fmed.2025.1574413","article-title":"Advancement and independent validation of a deep learning-based tool for automated scoring of nail psoriasis severity using the modified nail psoriasis severity index","volume":"12","author":"Kemenes","year":"2025","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.autrev.2025.103839_bb0365","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004273","article-title":"Deep learning-based classification of erosion, synovitis and osteitis in hand MRI of patients with inflammatory arthritis","volume":"10","author":"Schlereth","year":"2024","journal-title":"RMD Open"},{"issue":"20","key":"10.1016\/j.autrev.2025.103839_bb0370","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222010990","article-title":"Blood-based immune profiling combined with machine learning discriminates psoriatic arthritis from psoriasis patients","volume":"22","author":"Mulder","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103839_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152750","article-title":"Algorithmic approaches in hand imaging for rheumatic musculoskeletal diseases: a systematic literature review","volume":"73","author":"Perronne","year":"2025","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2025.103839_bb0380","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","article-title":"Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis","volume":"81","author":"Gisondi","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2025.103839_bb0385","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/annrheumdis-2021-220865","article-title":"Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis","volume":"81","author":"Acosta Felquer","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2025.103839_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(23)00034-6","article-title":"Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study","volume":"5","author":"Singla","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103839_bb0395","doi-asserted-by":"crossref","first-page":"257","DOI":"10.55563\/clinexprheumatol\/8thj0l","article-title":"Evidence that systemic therapies for psoriasis may reduce psoriatic arthritis occurrence","volume":"38","author":"Solmaz","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103839_bb0400","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/art.41946","article-title":"Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested case-control study","volume":"74","author":"Rosenthal","year":"2022","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2025.103839_bb0405","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13075-019-1957-0","article-title":"Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study","volume":"21","author":"Kampylafka","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.autrev.2025.103839_bb0410","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40744-024-00680-3","article-title":"From psoriasis to psoriatic arthritis: decoding the impact of treatment modalities on the prevention of psoriatic arthritis","volume":"11","author":"Watad","year":"2024","journal-title":"Rheumatol Ther"},{"issue":"4","key":"10.1016\/j.autrev.2025.103839_bb0415","first-page":"626","article-title":"Regression of peripheral subclinical Enthesopathy in therapy-naive patients treated with Ustekinumab for moderate-to-severe chronic plaque psoriasis: a fifty-two\u2013week, prospective","volume":"71","author":"Savage","year":"2019","journal-title":"Open-Label Feasibility Study Arthritis & Rheumatology"},{"issue":"suppl 9","key":"10.1016\/j.autrev.2025.103839_bb0420","article-title":"Effect of Apremilast on Disease Interception in Patients with Psoriasis at Increased Risk of Developing PsA \u2013 Results of the Prospective Interventional Epos Trial [abstract], in","volume":"75","author":"Simon","year":"2023","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.autrev.2025.103839_bb0425","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","article-title":"Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial","volume":"57","author":"Wells","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2025.103839_bb0430","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40259-025-00705-5","article-title":"Interleukin-23 versus Interleukin-17 inhibitors in preventing incidental psoriatic arthritis in patients with psoriasis: a real-world comparison from the TriNetX US collaborative network","volume":"39","author":"Yu","year":"2025","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.autrev.2025.103839_bb0435","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jaad.2024.06.106","article-title":"Risk of developing inflammatory arthritis in patients with psoriasis initiating treatment with biologics: a population-based analysis","volume":"91","author":"Strober","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2025.103839_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.ard.2025.01.006","article-title":"Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics","author":"Gisondi","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103839_bb0445","first-page":"213","article-title":"Reducing the risk of developing psoriatic arthritis in patients with psoriasis","volume":"12","author":"Gisondi","year":"2022","journal-title":"Psoriasis (Auckl)"},{"issue":"5","key":"10.1016\/j.autrev.2025.103839_bb0450","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/art.42780","article-title":"Difficult-to-treat psoriatic arthritis: a conceptual approach","volume":"76","author":"Fagni","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103839_bb0455","doi-asserted-by":"crossref","first-page":"21703","DOI":"10.1038\/s41598-020-78866-2","article-title":"Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis","volume":"10","author":"Rahmati","year":"2020","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.autrev.2025.103839_bb0460","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/annrheumdis-2021-220263","article-title":"Effectiveness of IL-12\/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results","volume":"80","author":"Smolen","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2025.103839_bb0465","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15755","article-title":"Therapeutic management and clinical remission for patients with psoriasis and psoriatic arthritis in a specialized dermatological-rheumatological center","volume":"35","author":"Ziob","year":"2022","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.autrev.2025.103839_bb0470","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-022-00874-5","article-title":"Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy","volume":"19","author":"Najm","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103839_bb0475","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/bjd.14270","article-title":"Combination of antitumour necrosis factor-\u03b1 and anti-interleukin-12\/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study","volume":"174","author":"Gniadecki","year":"2016","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103839_bb0480","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/rheumatology\/key199","article-title":"Combined inhibition of tumour necrosis factor-alpha and interleukin-12\/23 for long-standing, refractory psoriatic disease: a differential role for cytokine pathways?","volume":"57","author":"De Marco","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.autrev.2025.103839_bb0485","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1136\/annrheumdis-2022-222415","article-title":"Sequential interleukin-17\/interleukin-23 inhibition in treatment-refractory psoriatic arthritis","volume":"81","author":"Simon","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2025.103839_bb0490","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/rheumatology\/key069","article-title":"Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis","volume":"58","author":"Miyagawa","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2025.103839_bb0495","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2025.103839_bb0500","first-page":"275","article-title":"Efficacy and safety of Upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study","volume":"10","author":"McInnes","year":"2023","journal-title":"Rheumatol Ther"},{"issue":"10","key":"10.1016\/j.autrev.2025.103839_bb0505","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","article-title":"JAK inhibitor selectivity: new opportunities, better drugs?","volume":"20","author":"Virtanen","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103839_bb0510","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40264-023-01333-0","article-title":"Managing cardiovascular and Cancer risk associated with JAK inhibitors","volume":"46","author":"Yang","year":"2023","journal-title":"Drug Saf"},{"issue":"7","key":"10.1016\/j.autrev.2025.103839_bb0515","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/ard-2022-223636","article-title":"Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study","volume":"82","author":"Huss","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2025.103839_bb0520","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41584-024-01093-w","article-title":"TYK2: an emerging therapeutic target in rheumatic disease","volume":"20","author":"Morand","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103839_bb0525","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2025.103839_bb0530","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103839_bb0535","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2025.103839_bb0540","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.autrev.2025.103839_bb0545","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3109\/08916934.2016.1166214","article-title":"New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis","volume":"49","author":"Karczewski","year":"2016","journal-title":"Autoimmunity"},{"issue":"10","key":"10.1016\/j.autrev.2025.103839_bb0550","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2025.103839_bb0555","doi-asserted-by":"crossref","first-page":"1081644","DOI":"10.3389\/fcell.2022.1081644","article-title":"Clinical adoptive regulatory T cell therapy: state of the art, challenges, and prospective","volume":"10","author":"Amini","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.autrev.2025.103839_bb0560","article-title":"Regulatory T cells for minimising immune suppression in kidney transplantation: phase I\/IIa clinical trial","volume":"371","author":"Roemhild","year":"2020","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.autrev.2025.103839_bb0565","article-title":"Shared pathophysiology of inflammatory bowel disease and psoriasis: unraveling the connection","volume":"16","author":"Tabbarah","year":"2024","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.autrev.2025.103839_bb0570","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1053\/j.gastro.2012.07.116","article-title":"Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease","volume":"143","author":"Desreumaux","year":"2012","journal-title":"Gastroenterology"},{"issue":"20","key":"10.1016\/j.autrev.2025.103839_bb0575","doi-asserted-by":"crossref","first-page":"eadg6007","DOI":"10.1126\/sciadv.adg6007","article-title":"Adoptive T(reg) therapy with metabolic intervention via perforated microneedles ameliorates psoriasis syndrome","volume":"9","author":"Zhang","year":"2023","journal-title":"Sci Adv"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:05:47Z","timestamp":1762553147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225000990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":115,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1568997225000990"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103839","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in precision medicine in imaging and therapeutic strategies for psoriatic disease","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103839"}}